Gender differences in the effects of cardiovascular drugs

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 3, Issue 3, 2017, Pages 163-182

  Tamargo, J ^a,b   Rosano, G ^c,d   Walther, T ^e   Duarte, J ^b,f   Niessner, A ^g   Kaski, J C ^h   Ceconi, C ⁱ   Drexel, H ^j   Kjeldsen, K ^k,l   Savarese, G ^m   Torp Pedersen, C ^l   Atar, D ⁿ   Lewis, B S ^o   Agewall, S ^p  

^a SCHOOL OF MEDICINE   (Spain)

^b CIBERCV ^*  (Spain)

^c ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e UNIVERSITY COLLEGE CORK   (Ireland)

^f UNIVERSITY OF GRANADA   (Spain)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h ST GEORGE S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^j Landeskrankenhaus Feldkirch   (Austria)

^k HOLBÆK HOSPITAL   (Denmark)

^l AALBORG UNIVERSITY   (Denmark)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ OSLO UNIVERSITY HOSPITAL   (Norway)

^o TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^p ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Cardiovascular drugs; Gender; Pharmacodynamics; Pharmacokinetics; Sex

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE PURINERGIC P2Y12 RECEPTOR ANTAGONIST; ALDOSTERONE ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR II INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; IVABRADINE; LABETALOL; METOPROLOL; NITRIC ACID DERIVATIVE; PARACETAMOL; PROPROTEIN CONVERTASE 9 INHIBITOR; RENIN INHIBITOR; SACUBITRIL PLUS VALSARTAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ACUTE CORONARY SYNDROME; AGE; ANTICOAGULATION; AREA UNDER THE CURVE; ATRIAL FIBRILLATION; BLEEDING; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL PRACTICE; COUGHING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INFORMATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; ELECTROLYTE DISTURBANCE; GLOMERULUS FILTRATION RATE; HEART ATRIUM THROMBOSIS; HEART DEATH; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MENOPAUSE; MENSTRUAL CYCLE; MYOPATHY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PROCESS OPTIMIZATION; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL CLEARANCE; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SIDE EFFECT; SKIN DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOPLASTIN TIME; TORSADE DES POINTES; VENOUS THROMBOEMBOLISM; GLOBAL HEALTH; MORBIDITY; SEX FACTOR; SURVIVAL RATE; TRENDS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; GLOBAL HEALTH; HUMANS; MORBIDITY; SEX FACTORS; SURVIVAL RATE;

EID: 85043529821     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvw042     Document Type: Review

References (316)

1. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, Jonsson B, Schenck-Gustafsson K, Tendera M. Cardiovascular diseases in women: A statement from the Policy Conference of the European Society of Cardiology. Eur Heart J 2006;27:994-1005.
2. Maas AH, van der Schouw YT, Regitz-Zagrosek V, Swahn E, Appelman YE, Pasterkamp G, Ten Cate H, Nilsson PM, Huisman MV, Stam HC, Eizema K, Stramba-Badiale M. Red alert for women's heart: The urgent need for more research and knowledge on cardiovascular disease in women: Proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. Eur Heart J 2011;32:1362-1368.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 2015;131:e29-322.
4. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe-epidemiological update 2015. Eur Heart J 2015;36:2696-2705.
5. Garc-a M, Mulvagh SL, Merz NB, Buring JE, Manson JE. Cardiovascular disease in women. Clinical Perspectives. Circulation Res 2016;118:1273-1293.
6. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Pina IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK. Circulation 2011;123:1243-1262.
7. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 2006;5:425-438.
8. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. J Am Med Assoc 1992;268:1417-1422.
9. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. J Am Med Assoc 2007;297:1233-1240.
10. Kim ESH, Monon V. Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol 2009;29:279-283.
11. Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt) 2014;23:112-119.
12. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005;26:1585-1595.
13. Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J. Gender differences in the effect of cardiovascular drugs: A position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J 2015;36:2677-2680.
14. Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34:203-218.
15. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004;44:499-523.
16. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-239.
17. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics Clin Pharmacokinet 2002;41:329-342.
18. Soldin OP, Chung S, Mattison DR. Sex differences in drug disposition. J Biomed Biotechnol 2011;2011:187103.
19. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009;48:143-158.
20. EUGenMed Cardiovascular Clinical Study Group, Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, Franconi F, Gerdts E, Foryst-Ludwig A, Maas AH, Kautzky-Willer A, Knappe-Wegner D, Kintscher U, Ladwig KH, Schenck-Gustafsson K, Stangl V. Gender in cardiovascular diseases: Impact on clinical manifestations, management, and outcomes. Eur Heart J 2016;37:24-34.
21. Legato M. Gender and the heart: Sex-specific differences in normal anatomy and physiology. J Gend Specif Med 2000;3:15-18.
22. Huxley VH. Sex and the cardiovascular system: The intriguing tale of how women and men regulate cardiovascular function differently. Adv Physiol Educ 2007;31:17-22.
23. Oertelt-Prigione S, Regitz-Zagrosek V. Gender aspects in cardiovascular pharmacology. J Cardiovasc Trans Res 2009;2:258-266.
24. Nicolas J-M, Espie P, Molimard M. Gender and interindividual variability in pharmacokinetics. Drug Metabolism Rev 2009;41:408-421.
25. Anderson GD. Sex and racial differences in pharmacological response: Where is the evidence Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt) 2005;14:19-29.
26. Franconi F, Campese I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: Interaction with biological differences between men and women. Br J Clin Pharmacol 2014;171:580-594.
27. Stolarz AJ, Rusch NJ. Gender differences in cardiovascular drugs. Cardiovasc Drug Ther 2015;29:403-410.
28. Freire AC, Basit AW, Choudhary R, Piong CW, Merchant HA. Does sex matter The influence of gender on gastrointestinal physiology and drug delivery. Int J Pharm 2011;415:15-28.
29. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007;82:87-96.
30. Kimura T, Higaki K. Gastrointestinal transit and drug absorption. Biol Pharm Bull 2002;25:149-164.
31. Mojaverian P, Rocci ML Jr, Conner DP, Abrams WB, Vlasses PH. Effect of food on the absorption of enteric-coated aspirin: Correlation with gastric residence time. Clin Pharmacol Ther 1987;41:11-17.
32. Sica DA, Wood M, Hess M. Gender and its effect in cardiovascular pharmacotherapeutics: Recent considerations. Congest Heart Fail 2005;11:163-166.
33. Bock KW, Schrenk D, Forster A, Griese EU, Mö rike K, Brockmeier D, Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-218.
34. Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 2001;51:169-173.
35. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003;38:978-988.
36. Rademaker M. Do women have more adverse drug reactions Am J Clin Dermatol 2001;2:349-351.
37. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002;72:474-489.
38. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60.
39. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103-141.
40. Berg UB. Differences in decline in GFR with age between males and females: Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant 2006;21:2577-2582.
41. Spoletini I, Vitale C, Malorni W, Rosano GM. Sex differences in drug effects: Interaction with sex hormones in adult life. Handb Exp Pharmacol 2012;214:91-105.
42. Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost 2012;104:471-484.
43. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-3116.
44. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, Roe MT, Gibler WB, Ohman EM, Peterson ED. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 2006;114:1380-1387.
45. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, Bassand JP, De Caterina R, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KA, Kristensen SD, Rao SV, Verheugt FW, Widimsky P, Zeymer U, Collet JP. Bleeding in acute coronary syndromes and percutaneous coronary interventions: Position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011;32:1854-1864.
46. Jick H, Slone D, Borda IT, Shapiro S. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 1968;279:284-286.
47. Cipolle R, Seifert R, Neilan B, Zaske DE, Haus E. Heparin kinetics: Variables related to disposition and dosage. Clin Pharmacol Ther 1981;29:387-393.
48. Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Circulation 1996;93:870-878.
49. Hirsh J, O'donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: Current and future advances. Circulation 2007;116:552-560.
50. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. Thrombolysis in myocardial infarction 11A investigators. J Am Coll Cardiol 1997;29:1474-1482.
51. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM; TIMI 11A Investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002;143:753-759.
52. Cohen M, Antman EM, Gurfinkel EP, Radley D; ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events) and TIMI (Thrombolysis in Myocardial Infarction) 11B Investigators. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: Treatment benefits in prespecified subgroups. J Thromb Thrombolysis 2001;12:199-206.
53. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
54. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J 1999;137:72-78.
55. Mega JL, Morrow DA, Ostö r E, Dorobantu M, Qin J, Antman EM, Braunwald E. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation 2007;115:2822-2828.
56. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of theSYNERGY randomized trial. JAMA 2004;292:45-54.
57. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329.
58. Jang IK, Baron SJ, Hursting MJ, Anglade E. Argatroban therapy in women with heparin-induced thrombocytopenia. J Womens Health (Larchmt) 2007;16:895-901.
59. Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, Stone GW, Lansky AJ. Impact of bleeding and bivalirudin therapy on mortality risk in women undergoing percutaneous coronary intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). Am J Cardiol 2016;117:186-191.
60. Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J 2006;151:1032.e1-1037.
61. Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol 2009;103:1196-1203.
62. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, Ohman EM, Stone GW. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY Trial. J Am Coll Cardiol 2007;49:1362-1368.
63. Madsen JK, Chevalier B, Darius H, Rutsch W, Wojcik J, Schneider S, Allikmets K. Ischaemic events and bleeding in patients undergoing percutaneous coronary intervention with concomitant bivalirudin treatment. EuroIntervention 2008;3:610-616.
64. Shammas NW, Allie D, Hall P, Young J, Laird J, Safian R, Virmani A; APPROVE Investigators. Predictors of in-hospital and 30-day complications of peripheral vascular interventions using bivalirudin as the primary anticoagulant: Results from the APPROVE Registry. J Invasive Cardiol 2005;17:356-359.
65. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
66. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703.
67. Roguin A, Steinberg BA, Watkins SP, Resar J.R. Safety of bivalirudin during percutaneous coronary interventions in patients with abnormal renal function. Int J Cardiovasc Intervent 2005;7:88-92.
68. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
69. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. J Am Med Assoc 2006;295:1519-1530.
70. Oldgren J, Wallentin L, Afzal R, Bassand JP, Budaj A, Chrolavicius S, Fox KA, Granger CB, Mehta SR, Pais P, Peters RJ, Xavier D, Zhu J, Yusuf S; OASIS-6 Investigators. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J 2008;29:315-323.
71. Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M, Volgman AS, Petersen P, Frison L, Halperin JL. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 2006;27:1947-1953.
72. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999;30:1223-1229.
73. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112:1687-1691.
74. [No authors listed]. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
75. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-1562.
76. Pengo V, Legnani C, Noventa F, Palareti G; ISCOAT Study Group (Italian Study on Complications of Oral Anticoagulant Therapy). Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost 2001;85:418-422.
77. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: Implications for safer anticoagulation in the elderly population. Chest 2005;127:2049-2056.
78. Horton JD, Bushwick BM. Warfarin therapy: Evolving strategies in anticoagulation. Am Fam Physician 1999;59:635-646.
79. Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2013;53:249-255.
80. Jiang J, Hu Y, Zhang J, Yang J, Mueck W, Kubitza D, Bauer RJ, Meng L, Hu P. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban-an oral, direct Factor Xa inhibitor-in elderly Chinese subjects. Thromb Haemost 2010;103:234-241.
81. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
82. Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, Harris SI, LaCreta F. Effects of age and sex on the single dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet 2015;54:651-662.
83. Mendell J, Shi M. Safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of edoxaban in healthy post-menopausal or surgically sterile females, and healthy elderly males. ESC Eur Heart J 2011;32:461.
84. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
85. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-295.
86. Sanford M, Plosker GL. Dabigatran etexilate. Drugs 2008;68:1699-1709.
87. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
88. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
89. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817.
90. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI,-Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104.
91. Vallurupalli S, Deshmukh A, Paydak H. Gender based differences in benefit from novel oral anticoagulant drugs compared to warfarin in atrial fibrillation: An analysis of published studies. J Am Coll Cardiol 2014;63:A320.
92. Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, M-argulescu AD, Wallentin L, Atar D. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: A secondary analysis of a randomized controlled trial. Eur Heart J 2015;36:3268-3275.
93. Dentali F, Sironi AP, Gianni M, Orlandini F, Guasti L, Grandi AM, Franchini M, Ageno W, Squizzato A. Gender difference in efficacy and safety of nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation or venous thromboembolism: A systematic review and a meta-analysis of the literature. Semin Thromb Hemost 2015;41:774-787.
94. Brauer KA, Homering M, Berkowitz SD. Effects of age, weight, gender and renal function in a pooled analysis of four phase III studies of rivaroxaban for prevention of venous thromboembolism after major orthopedic surgery. Blood 2008;112:436.
95. Alotaibi GS, Almodaimegh H, McMurtry MS, Wu C. Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis. Thromb Res 2013;132:185-189.
96. Loffredo L, Violi F, Perri L. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A metaanalysis of the interventional trials. Int J Cardiol 2016;212:255-258.
97. Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014;113:485-490.
98. Escolar G, Bastida E, Garrido M, Rodr-?guez-G-omez J, Castillo R, Ordinas A. Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium. Thromb Res 1986;44:837-847.
99. Bain B, Forester T. A sex difference in the bleeding time. Thromb Haemost 1980;3:131-132.
100. Patti G, De Caterina R, Abbate R, Andreotti F, Biasucci LM, Calabr-o P, Cioni G, Dav-? G, Di Sciascio G, Golia E, Golino P, Malatesta G, Mangiacapra F, Marcucci R, Nusca A, Parato VM, Pengo V, Prisco D, Pulcinelli F, Renda G, Ricottini E, Ruggieri B, Santilli F, Sofi F, Zimarino M; Working Group on Thrombosis of the Italian Society of Cardiology. Platelet function and long-term antiplatelet therapy in women: Is there a gender-specificity? A 'state-of-the-art' paper. Eur Heart J 2014;35:2213-2223.
101. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 1997;77:748-754.
102. Zwierzina WD, Kunz F, Kogelnig R, Herold M. Sex-related differences in platelet aggregation in native whole blood. Thromb Res 1987;48:161-171.
103. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975;253:355-357.
104. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005;106:2723-2729.
105. Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O. 17 betaestradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab 1995;80:1832-1836.
106. Caulin-Glaser T, Garc-?a-Carde~na G, Sarrel P, Sessa WC, Bender J.R. 17 betaestradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2\+ mobilization. Circ Res 1997;81:885-892.
107. Arora S, Veves A, Caballaro AE, Smakowski P, LoGerfo FW. Estrogen improves endothelial function. J Vasc Surg 1998;27:1141-1146.
108. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
109. Pinto S, Coppo M, Paniccia R, Prisco D, Gori AM, Attanasio M, Abbate R. Sex related differences in platelet TxA2 generation. Prostaglandins Leukot Essent Fatty Acids 1990;40:217-221.
110. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 1995;91:2742-2747.
111. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
112. Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL, LaCroix AZ, Ridker PM. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study. Thromb Haemost 2005;93:1108-1116.
113. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
114. Patrono C, Garc-?a Rodr-?guez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383.
115. Collaboration Antithrombotic Trialists, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860.
116. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. Jama 2006;295:1420-1427.
117. Harrison MJ, Weisblatt E. A sex difference in the effect of aspirin on "spontaneous" platelet aggregation in whole blood. Thromb Haemost 1983;50:773-774.
118. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
119. Cavallari LH, Helgason CM, Brace LD, Viana MA, Nutescu EA. Sex difference in the antiplatelet effect of aspirin in patients with stroke. Ann Pharmacother 2006;40:812-817.
120. Buchanan MR, Rischke JA, Butt R, Turpie AG, Hirsh J, Rosenfeld J. The sexrelated differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. Thromb Res 1983;29:125-139.
121. Ho PC, Triggs EJ, Bourne DW, Heazlewood VJ. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites. Br J Clin Pharmacol 1985;19:675-684.
122. Miners JO, Grugrinovich N, Whitehead AG, Robson RA, Birkett DJ. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br J Clin Pharmacol 1986;22:135-142.
123. Spranger M, Aspey BS, Harrison MJ. Sex difference in antithrombotic effect of aspirin. Stroke 1989;20:34-37.
124. Haque SF, Matsubayashi H, Izumi S, Sugi T, Arai T, Kondo A, Makino T. Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J 2001;48:33-41.
125. Samad Z, Boyle S, Ersboll M, Vora AN, Zhang Y, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers JG, O'connor CM, Velazquez EJ, Jiang W; REMIT Investigators. Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: Insights from the REMIT study. J Am Coll Cardiol 2014;64:1669-1678.
126. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.
127. Berger JS, Roncaglioni MC, Avanzini F, Pangrzzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex specific meta-analysis of randomized controlled trials. Jama 2006;295:306-313.
128. Xie M, Shan Z, Zhang Y, Chen S, Yang W, Bao W, Rong Y, Yu X, Hu FB, Liu L. Aspirin for primary prevention of cardiovascular events: Meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One 2014;9:e90286.
129. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
130. Yerman T, Gan WQ, Sin DD. The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med 2007;5:29.
131. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de WF, de TA, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
132. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: Pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000;36:381-386.
133. Fernandes LS, Tcheng JE, O'shea JC, Weiner B, Lorenz TJ, Pacchiana C, Berdan LG, Maresh KJ, Joseph D, Madan M, Mann T, Kilaru R, Hochman JS, Kleiman NS; ESPRIT Investigators. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. J Am Coll Cardiol 2002;40:1085-1091.
134. James SK, Stenestrand U, Lindback J, Carlsson J, Scherstén F, Nilsson T, Wallentin L, Lagerqvist B; SCAAR Study Group. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009;360:1933-1945.
135. Dziewierz A, Siudak Z, Rakowski T, Kleczy-nski P, Dubiel JS, Dudek D. Early administration of abciximab reduces mortality in female patients with STelevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry). J Thromb Thrombolysis 2013;36:240-246.
136. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
137. Price MJ. Monitoring platelet function to reduce the risk of ischemic and bleeding complications. Am J Cardiol 2009;103(Suppl.):35A-39A.
138. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: Current status and future directions. Thromb Haemost 2009;102:7-14.
139. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PB. The relative efficacy and safety of clopidogrel in women and men: A sex-specific collaborative meta-analysis. Am Coll Cardiol 2009;54:1935-1945.
140. Zaccardi F, Pitocco D, Willeit P, Laukkanen JA. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials. Atherosclerosis 2015;240:439-445.
141. Wrishko RE, Ernest CS II, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, Macias WL, Rohatagi S, Salazar DE, Antman EM, Wiviott SD, Braunwald E, Ni L. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure ofprasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol 2009;49:984-998.
142. Ernest CS II, Small DS, Rohatagi S, Salazar DE, Wallentin L, Winters KJ, Wrishko RE. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodyn 2008;35:593-618.
143. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
144. Hochholzer W, Wiviott SD, Antman EM, Contant CF, Guo J, Giugliano RP, Dalby AJ, Montalescot G, Braunwald E. Predictors of bleeding and time dependence of association of bleeding with mortality: Insights from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in myocardial infarction 38 (TRITON-TIMI 38). Circulation 2011;123:2681-2689.
145. Chandrasekhar J, Baber U, Sartori S, Faggioni M, Aquino M, Kini A, Weintraub W, Rao S, Kapadia S, Weiss S, Strauss C, Toma C, Muhlestein B, DeFranco A, Effron M, Keller S, Baker B, Pocock S, Henry T, Mehran R. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS Study. Catheter Cardiovasc Interv 2016; doi: 10.1002/ccd.26606.
146. Teng R. Ticagrelor: Pharmacokinetic, pharmacodynamic and pharmacogenetic profile: An update. Clin Pharmacokinet 2015;54:1125-1138.
147. Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATO study group. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2014;35:1541-1550.
148. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
149. O'Donoghue ML, Bhatt DL, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Deliargyris EN, Mahaffey KW, White HD, Harrington RA; CHAMPION PHOENIX Investigators. Efficacy and safety of cangrelor in women versus men during percutaneous coronary intervention: Insights from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION PHOENIX) Trial. Circulation 2016;133:248-255.
150. Kam KW, Qi JS, Chen M, Wong TM. Estrogen reduces cardiac injury and expression of beta1-adrenoceptor upon ischemic insult in the rat heart. J Pharmacol Exp Ther 2004;309:8-15.
151. Thawornkaiwong A, Preawnim S, Wattanapermpool J. Upregulation of b1-A drenergic receptors in ovariectomized rat hearts. Life Sci 2003;72: 1813-1824.
152. Fletcher A, Beevers DG, Bulpitt C, Butler A, Coles EC, Hunt D, Munro-Faure AD, Newson RB, O'riordan PW, Petrie JC. Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: A report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens 1988;2:219-227.
153. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Genderrelated effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999;66:594-601.
154. Walle T, Byington RP, Furberg CD, McIntyre KM, Vokonas PS. Biologic determinants of propranolol disposition: Results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 1985;38:509-518.
155. Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989;46:257-263.
156. Kendall MJ, Quarterman CP, Jack DB, Beeley L. Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol 1982;14:120-122.
157. Cocco G, Chu D. The anti-ischemic effect of metoprolol in patients with chronic angina pectoris is gender-specific. Cardiology 2006;106:147-153.
158. The beta-blocker heart attack trial. beta-Blocker Heart Attack Study Group. JAMA 1981; 246:2073-2074.
159. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
160. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;334:1651-1658.
161. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199.
162. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC. Metoprolol CR/XL in female patients with heart failure: Analysis of the experience in metoprolol extended-release randomized intervention trial in heart failure (MERIT-HF). Circulation 2002;105:1585-1591.
163. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: A meta-analysis on individual data of two placebocontrolled studies-CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002;143:301-307.
164. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
165. Ghali JK. Sex-related differences in heart failure and beta-blockers. Heart Fail Rev 2004;9:149-159.
166. Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW, Young JB, Goldman S, Peberdy MA, Lindenfeld J. Gender differences in advanced heart failure: Insights from the BEST study. J Am Coll Cardiol 2003;42:2128-2134.
167. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L. Efficacy of angiotensin-converting enzyme inhibitors and betablockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-1538.
168. Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJ, Cleland JG, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GY, van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD; Beta-Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of b blockers in patients with heart failure with reduced ejection fraction: Individual patient data meta-analysis. Bmj 2016;353:i18.
169. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: Continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther 2000;68:286-292.
170. Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB. Population analyses of sustained-release verapamil in patients: Effects of sex, race, and smoking. Clin Pharmacol Ther 2003;73:31-40.
171. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB. Race and sex influence clearance of nifedipine: Results of a population study. Clin Pharmacol Ther 2000;68:130-142.
172. Abad-Santos F, Novalbos J, G-alvez-M-ugica MA, Gallego-Sand-?n S, Almeida S, Valleé F, Garc-?a AG. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res 2005;51:445-452.
173. Dadashzadeha S, Javadiana B, Sadeghianb S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm. Drug Dispos 2006;27:329-334.
174. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003;42:107-121.
175. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M; For the Amlodipine Cardiovascular Community Trial Study Group. Sex-A nd age-related antihypertensive effects of amlodipine. Am J Cardiol 1996;77:713-722.
176. Kjeldsen SE, Kolloch RE, Leonetti G, Malliond J-M, Zanchetti A, Elmfeldt D, Warnold I, Hansson L; For the HOT Study Group. Influence of gender and age on the preventing cardiovascular disease by antihypertensive treatment and acetysalicyl acid. The HOT Study. J Hypertens 2000;18:629-642.
177. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-1411.
178. Adams KF Jr, Patterson JH, Gattis WA, O'connor CM, Lee CR, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: A retrospective analysis. J Am Coll Cardiol 2005;46:497-504.
179. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. Jama 2003;289:871-878.
180. Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O'connor CM, Reynolds D, Walsh MN. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: Findings from improve HF. Am Heart J 2009;157:754-762.e2.
181. Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail 2005;11:83-86.
182. Lee LS, Chan LN. Evaluation of a sex-based difference in the pharmacokinetics of digoxin. Pharmacotherapy 2006;26:44-50.
183. Blaustein MP, Robinson SW, Gottlieb SS, Balke CW, Hamlyn JM. Sex, digitalis, and the sodium pump. Mol Interv 2003;3:68-72.
184. Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, Hulley S. Subgroup interactions in the heart and estrogen/progestin replacement study: Lessons learned. Circulation 2002;105:917-922.
185. Werner U, Werner D, Heinbüchner S, Graf B, Ince H, Kische S, Thürmann P, Kö nig J, Fromm MF, Zolk O. Gender is an important determinant of the disposition of the loop diuretic torasemide. J Clin Pharmacol 2010;50:160-168.
186. Chapman MD, Hanrahan R, McEwen J, Marley JE. Hyponatremia and hypokalemia due to indapamide. Med J Aust 2002;176:219-221.
187. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res 2010;106:434-446.
188. Tardif J-C, Ford I, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of ivabradine, a new selective Ifinhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-2536.
189. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: A 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67:393-405.
190. Tendera M, Borer JS, Tardif JC. Efficacy of If inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology 2009;114:116-125.
191. Fox K, Ford I, Steg PG, Tendera M, Ferrari M; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816.
192. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010;376:875-885.
193. Tamargo J. The mechanism of action of LCZ696. Cardiac Failure Review 2016;2:40-46.
194. Gan L, Langenickel T, Petruck J, Kode K, Rajman I, Chandra P, Zhou W, Rebello S, Sunkara G. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol 2016;56:78-86.
195. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees Investigators., Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2014;16:817-825.
196. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
197. Vree TB, Dammers E, Valducci R. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. Int J Clin Pharmacol Ther 2004;42:463-472.
198. PraluentVR Summary of Product Characteristics. www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/003882/WC500194521. pdf (20 February 2017).
199. RepathaVR Summary of Product Characteristics. 1http://ec.europa.eu/health/documents/community-register/2015/20150717132330/anx-132330-es.pdf (20 February 2017).
200. Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, Louie MJ, Raal FJ. Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the Phase 3 ODYSSEY Program). Am J Cardiol 2017;119:40-46.
201. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): A pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014;63:1278-1288.
202. Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 2014;65:417-431.
203. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002;53:672-677.
204. Sullivan JC. Sex and the renin-angiotensin system: Inequality between the sexes in response to ras stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol 2008; 294:R1220-R1226.
205. Komukai K, Mochizuki S, Yoshimura M. Gender and the renin-angiotensinaldosterone system. Fundam Clin Pharmacol 2010;24:687-698.
206. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14:73-86.
207. Jarugula V, Yeh CM, Howard D, Bush C, Keefe DL, Dole WP. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren. J Clin Pharmacol 2010;50:1358-1366.
208. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. A comparison of outcomes with angiotensin converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592.
209. Ljungman C, Kahan T, Schiö ler L, Hjerpe P, Hasselström J, Wettermark B, Boström KB, Manhem K. Gender differences in antihypertensive drug treatment: Results from the Swedish Primary Care Cardiovascular Database (SPCCD). J Am Soc Hypertens 2014;8:882-890.
210. Moretti ME, Caprara D, Drehuta I, Yeung E, Cheung S, Federico L, Koren G. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int 2012;2012:658310.
211. Cooper WO. Clinical implications of increased congenital malformations after first trimester exposures toangiotensin-converting enzyme inhibitors. J Cardiovasc Nurs 2008;23:20-24.
212. Walfisch A, Al-Maawali A, Moretti ME, Nickel C, Koren G. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 2011;31:465-472.
213. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: Cause or confounding? Br J Clin Pharmacol 1999;47:111-114.
214. Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female sex as an important determinant of lisinopril induced-cough. Lancet 1992;339:372.
215. Strocchi E, Malini PL, Valtancoli G, Ricci C, Bassein L, Ambrosioni E. Cough during treatment with angiotensin-converting enzyme inhibitors. Analysis of predisposing factors. Drug Invest 1992;4:69-72.
216. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The Consensus Trial Study Group. N Engl J Med 1987;316:1429-1435.
217. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
218. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992;327:685-691.
219. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study Investigators. N Engl J Med 2000;342:145-153.
220. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-828.
221. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456.
222. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E; For the ACE inhibitor myocardial infarction collaborative group. Long-term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet 2000;355:1575-1581.
223. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
224. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
225. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, deFaire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
226. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760.
227. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
228. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003;362:759-766.
229. Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM; VALIANT Investigators. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: Baseline characteristics in context. Eur J Heart Fail 2003;5:537-544.
230. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-2031.
231. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
232. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone in morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
233. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-952.
234. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C, Rabi D, Tremblay J, Alamian A, Barnett T, Cox J, Ghali WA, Grace S, Hamet P, Ho T, Kirkland S, Lambert M, Libersan D, O'loughlin J, Paradis G, Petrovich M, Tagalakis V. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007;176:S1-S44.
235. Virani SS, Woodard LD, Ramsey DJ, Urech TH, Akeroyd JM, Shah T, Deswal A, Bozkurt B, Ballantyne CM, Petersen LA. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol 2015;115:21-26.
236. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-152.
237. Bang CN, Okin PM. Statin treatment, new-onset diabetes, and other adverse effects: A systematic review. Curr Cardiol Rep 2014;16:461-464.
238. Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother 2014;5:181-185.
239. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am Coll Cardiol 2016;67:2395-2410.
240. Sirtori C. The pharmacology of statins. Pharmacol Res 2014;88:3-11.
241. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640-651.
242. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012;59: 572-582.
243. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-1405.
244. Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381.
245. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-2313.
246. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: A network metaanalysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-1781.
247. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
248. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
249. Karmali KN, Lloyd-Jones DM, Berendsen MA, Goff DC Jr, Sanghavi DM, Brown NC, Korenovska L, Huffman MD. Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. JAMA Cardiol 2016;1:341-349.
250. NICE Clinical guideline [CG181], Cardiovascular disease: Risk assessment and reduction, including lipid modification. www.nice.org.uk/guidance/cg181/evi dence/lipid-modification-update-full-guideline-243786637 (20 February 2017).
251. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force On Practice Guidelines. Circulation 2014;129:S1-S45.
252. Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, Blough D, Stergachis A, Chan KA, Platt R, Shatin D. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007;16: 352-358.
253. Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng DS, Pearson GJ, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013;29:1553-1568.
254. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözo-glu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg, HN; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-1022.
255. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, Aronow WS, Athyros V, Djuric DM, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z, Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Broncel M, Nikolic D, Pella D, Puri R, Rysz J, Wong ND, Bajnok L, Jones SR, Ray KK, Mikhailidis DP. Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf 2015;14:935-955.
256. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
257. Razakjr OA, Tan HC, Yip WL, Lim YT. Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention. J Interv Cardiol 2005;18:33-37.
258. Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM; For the GUSTO-I Investigators. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I Investigators. JAMA 1996;275:777-782.
259. Reynolds HR, Farkouh ME, Lincoff AM, Hsu A, Swahn E, Sadowski ZP, White JA, Topol EJ, Hochman JS; Gusto V Investigators. Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med 2007;167:2054-2060.
260. Moen EK, Asher CR, Miller DP, Weaver WD, White HD, Califf RM, Topol EJ. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries. J Womens Health 1997;6:285-293.
261. Mehta RH, Stebbins AS, Lopes RD, Califf RM, Pieper KS, Armstrong PW, Van de Werf F, Hochman JS, White HD, Topol EJ, Alexander JH, Granger CB. Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. Am J Cardiol 2012;109:320-326.
262. Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, Armstrong PW, Topol EJ, Califf RM. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997;95:2508-2516.
263. Moscucci M, Fox KA, Cannon CP, Klein W, L-opez-Send-on J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-1823.
264. Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, Pehrsson K, Verheugt FW, Meyer J, Betriu A, Califf RM, Li X, Fox NL; ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: A comparison of TNK-tPA and rt-PA. Eur Heart J 2001;22:2253-2261.
265. White HD, Barbash GI, Modan M, Simes J, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EA. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. Circulation 1993;88:2097-2103.
266. Gurwitz JH, Gore JM, Goldberg RJ, Barron HV, Breen T, Rundle AC, Sloan MA, French W, Rogers WJ. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998;129:597-604.
267. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
268. Woodfield SL, Lundergan CF, Reiner JS, Thompson MA, Rohrbeck SC, Deychak Y, Smith JO, Burton JR, McCarthy WF, Califf RM, White HD, Weaver WD, Topol EJ, Ross AM. Gender and acute myocardial infarction: Is there a different response to thrombolysis J Am Coll Cardiol 1997;29:35-42.
269. Gruppo Italiano per lo Studio Della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
270. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
271. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton J.R. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;2:525-530.
272. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
273. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Circulation 1995;91:1659-1668.
274. Becker RC, Hochman JS, Cannon CP, Spencer FA, Ball SP, Rizzo MJ, Antman EM. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: Observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol 1999;33:479-487.
275. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke. A pooled analysis of randomized clinical trials. Stroke 2005;36:62-65.
276. Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. Drugs 1995;50:1-6.
277. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: Analysis of 48 cohort studies. Br J Clin Pharmacol 1998;46:505-511.
278. Zopf Y, Rabe C, Neubert A, Gassmann KG, Rascher W, Hahn EG, Brune K, Dormann H. Women encounter ADRs more often than do men. Eur J Clin Pharmacol 2008;64:999-1004.
279. Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci 2010;31:108-114.
280. Tharpe N. Adverse drug reactions in women's health care. J Midwifery Womens Health 2011;5656:205-213.
281. Bugiardini R, Yan AT, Yan RT, Fitchett D, Langer A, Manfrini O, Goodman SG; Canadian Acute Coronary Syndrome Registry I and II Investigators. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J 2011;32:1337-1344.
282. Parekh A, Fadiran EO, Uhl K, Throckmorton DC. Adverse effects in women: Implications for drug development and regulatory policies. Expert Rev Clin Pharmacol 2011;4:453-466.
283. US General Accounting Office (GAO). Drug safety: Most drugs withdrawn in jrecent years had greater health risks for women. Washington, DC: GAO; 2001. www.gao.gov/new.items/dOI286r. pdf (20 February 2017).
284. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
285. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex differences in risk of torsades de pointes with d,l-sotalol. Circulation 1996;94:2535-2541.
286. Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM, Pitt B, Schwartz PJ, Veltri EP, Waldo AL; For the SWORD Investigators. Mortality in the Survival With ORal D-Sotalol (SWORD) trial: Why did patients die Am J Cardiol 1998;81:869-876.
287. Torp-Pederson C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm JA. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Eng J Med 1999;341:857-865.
288. Drici MD, Clement N. Is gender a risk factor for adverse drug reactions The example of drug-induced long QT syndrome. Drug Safety 2001;24:575-585.
289. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-1372.
290. Peters RW, Gold MR. Influence of Gender on Arrhythmias. Cardiol Rev 2004;12:97-105.
291. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev 2010;62:760-781.
292. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001;285:1322-1326.
293. Nakagawa M, Ooie T, Takahashi N, Taniguchi Y, Anan F, Yonemochi H, Saikawa T. Influence of menstrual cycle on QT interval dynamics. Pacing Clin Electrophysiol 2006;29:607-613.
294. Jonsson MK, Vos MA, Duker G, Demolombe S, van Veen TA. Gender disparity in cardiac electrophysiology: Implications for cardiac safety pharmacology. Pharmacol Ther 2010;127:9-18.
295. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, Davignon A. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8:690-695.
296. Liu XK, Katchman A, Drici MD, Ebert SN, Ducic I, Morad M, Woosley RL. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther 1998;285:672-679.
297. Kurokawa J, Kodama M, Clancy CE, Furukawa T. Sex hormonal regulation of cardiac ion channels in drug-induced QT syndromes. Pharmacol Ther 2016;168:23-28.
298. Gaborit N, Varro A, Le Bouter S, Szuts V, Escande D, Nattel S, Demolombe S. Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. J Mol Cell Cardiol 2010;49:639-646.
299. Larsen JA, Tung RH, Sadananda R, Goldberger JJ, Horvath G, Parker MA, Kadish AH. Effects of hormone replacement therapy on QT interval. Am J Cardiol 1998;82:993-995.
300. Arya A. Gender-related differences in ventricular repolarization: Beyond gonadal steroids. J Cardiovasc Electrophysiol 2005;16:525-527.
301. Hreiche R, Morissette P, Turgeon J. Drug-Induced Long QT Syndrome in Women: Review of Current Evidence and Remaining Gaps. Gend Med 2008;5:124-135.
302. Institute of Medicine (US) Committee on Women's Health Research, Board on Population Health. Women's Health Research: Progress, Pitfalls, and Promise. Washington, DC: National Academies Press; 2010.
303. Wallach Kildemoes H, Hendriksen C, Andersen M. Drug utilization according to reason for prescribing: A pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiol Drug Saf 2012;21:1027-1035.
304. Chou AF, Scholle SH, Weisman CS, Bierman AS, Correa-de-Araujo R, Mosca L. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues 2007;17:120-130.
305. Lenzen MJ, Rosengren A, Scholte OP, Reimer WJ, Follath F, Boersma E, Simoons ML, Cleland JG, Komajda M. Management of patients with heart failure in clinical practice: Differences between men and women. Heart 2008;94:e10.
306. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX Jr, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby LK; CRUSADE Investigators. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: Largescale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005;45:832-837.
307. Seeland U, Regitz-Zagrosek V. Sex and Gender Differences in Cardiovascular Drug Therapy. Handb Exp Pharmacol 2012;214:211-236.
308. Baumhakel M, Muller U, Bohm M. Influence of Gender of Physicians and Patients on Guideline-Recommended Treatment of Chronic Heart Failure in a Cross-Sectional Study'. Eur J Heart Fail 2009;11:299-303.
309. Enriquez JR, Pratap P, Zbilut JP, Calvin JE, Volgman AS. Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. Gend Med 2008;5:53-61.
310. Schulman KA, Berlin JA, Harless W, Kerner JF, Sistrunk S, Gersh BJ, Dubé R, Taleghani CK, Burke JE, Williams S, Eisenberg JM, Escarce JJ. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999;340:618-626.
311. Kim C, Carrigan TP, Menon V. Enrollment of women in National Heart, Lung, and Blood Institute-Funded cardiovascular controlled trials fails to meet current federal mandates for inclusion. JACC 2008;52:672-673.
312. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studied. Nature 2014;509:282-283.
313. National Institutes of Health. NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Fed Regist 1994;59:14508-14513.
314. Office of Extramural Research NIH. NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research-Amended, October 2001. Department of Health and Human Services, National Institutes of Health. https://grants.nih.gov/grants/funding/women-min/guidelines-amended-10-2001.htm (20 February 2017).
315. Johnson SM, Karvonen CA, Phelps CL, Nader S, Sanborn BM. Assessment of analysis by gender in the Cochrane reviews as related to treatment of cardiovascular disease. J Womens Health (Larchmt) 2003;12:449-457.
316. Geller SE, Koch A, Pellettieri B, Carnes M. Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: Have we made progress J Womens Health 2011;20:215-220.